Clinical Trials Logo

Cognition Disorders clinical trials

View clinical trials related to Cognition Disorders.

Filter by:

NCT ID: NCT01479855 Recruiting - Clinical trials for Mild Cognitive Impairment

Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type

ALZ-vit
Start date: January 2012
Phase: N/A
Study type: Observational

The purpose of the study is to compare the concentrations of Vitamin B1 (thiamine), Vitamin B6 (pyridoxal-5-phosphate), folate, Vitamin B12 (cobalamin), Vitamin C (ascorbic acid), Vitamin A (retinol), Vitamin E (alfa-tocopherol), homocystein, uric acid, F2 8-α-isoprostane, 8-deoxyguanosine, retinoids, tau-protein and β-amyloid in spinal fluid, metabolomics, proteomics, m-RNA for DNA repair enzymes and DNA in patients who suffer from mild cognitive impairment (MCI) or mild dementia of Alzheimers type, with healthy controls. A second aim is to explore the association between vitamin and nutrient reductions, if any, and cognitive function as well as vascular score and possible changes in the MRI.

NCT ID: NCT01466270 Completed - Breast Cancer Clinical Trials

Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction

Start date: July 2012
Phase: Phase 2
Study type: Interventional

RATIONALE: Donepezil hydrochloride may help lessen cognitive dysfunction caused by chemotherapy. PURPOSE: This phase II trial is studying donepezil hydrochloride in treating cognitive dysfunction after chemotherapy in female breast cancer survivors.

NCT ID: NCT01466205 Recruiting - Clinical trials for Cognitive Impairments

Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder

SPD
Start date: January 2011
Phase: Phase 2
Study type: Interventional

Currently, no study to date has directly tested a selective D1R agonist in relation to the cognitive impairment of Schizophrenia without the confound of neuroleptics. The investigators propose to examine the efficacy of DAR-0100A, a highly selective, full D1R agonist supported by pre-clinical and preliminary pilot clinical data, in ameliorating the cognitive deficits in Schizotypal Personality Disordered subjects receiving no medications including antipsychotics. The investigators hypothesize that 1) Baseline primary outcome measures will be impaired in Schizotypal personality disorder (SPD) subjects compared to controls, 2) SPD subjects on DAR-0100A will show improvement on primary measures greater than healthy controls and SPD patients randomized to placebo, and 3) SPD patients will show significant improvements on primary outcome variables on drug compared to placebo.

NCT ID: NCT01465360 Completed - Clinical trials for Mild Cognitive Impairment

Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

Start date: November 2011
Phase: N/A
Study type: Observational

The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients having memory impairments.

NCT ID: NCT01463384 Completed - Clinical trials for Mild Cognitive Impairment

Minocycline in Patients With Alzheimer's Disease

Start date: September 2011
Phase: Phase 2
Study type: Interventional

Cognitively normal individuals, patients with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) will undergo clinical screening, neuropsychological tests, blood and urine analyses, quantitative magnetic resonance imaging (MRI) and proton (1H ) and carbon 13 (13C) magnetic resonance spectroscopy (MRS). Each individual will receive minocycline oral administration for 4 weeks initially, after which MRI, MRS and neuropsychological results will be recorded. If no adverse side effects occur, subjects will continue minocycline administration for an additional 5 months.

NCT ID: NCT01461629 Completed - Heart Failure Clinical Trials

Self-management and Cognitive Function in Adults With Heart Failure

Heart ABC
Start date: June 2010
Phase: N/A
Study type: Observational

The purpose of this study is to assess the relationship between cognitive impairment, patient self-management, health, and health service use in adults with heart failure (NYHA Class 2 and 3). The research questions are: 1. How is cognitive impairment (memory, attention, global and executive function) related to various aspects of impaired self-management (knowledge of adherence, adherence to sodium restriction and medications, symptom monitoring of weight changes, and decision and action to seek care)? 2. How are these relationships altered when adjusting for medical, demographic, and psychosocial factors? 3. What are the relationships among degree of cognitive impairment, quality self-management, health status, and health service use?

NCT ID: NCT01453569 Completed - Alzheimer Disease Clinical Trials

Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease

Start date: October 2011
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine whether sodium oligo-mannurarate capsule is effective and safe in the treatment of mild to moderate alzheimer' disease, and to determine the best therapeutic dose of sodium oligo-mannurarate capsule.

NCT ID: NCT01451749 Completed - Clinical trials for Mild Cognitive Impairment

Efficacy and Safety Study of Shenwu Capsule

Start date: September 2008
Phase: Phase 3
Study type: Interventional

The purpose of this phase III study is to further evaluate the effects of shenwu capsule, a traditional Chinese herbal medicine, on cognition, function and memory in patients with amnestic mild cognitive impairment (MCI) who are at greater risk for developing Alzheimer's disease, in a 6-month supervised protocol of a traditional Chinese herbal medicine. The results of this study may provide support for a relatively simple and inexpensive treatment strategy with herbal therapy that specifically targets individuals with the mild cognitive impairment that directly influence risk of developing dementia for older adults.

NCT ID: NCT01448148 Completed - Clinical trials for Mild Cognitive Impairment

Measuring the Impact of Cognitive and Psychosocial Interventions in Persons With Mild Cognitive Impairment

Start date: November 2011
Phase: N/A
Study type: Interventional

Memory interventions are training programs that provide a variety of cognitive and psychological strategies meant to improve memory. These interventions have been shown to yield significant benefits to normal aged persons and small-size studies have shown that they are suitable and beneficial for persons with mild cognitive impairment. The goal of this proposal is to assess with a well-controlled design the efficiency and specificity of cognitive training in persons with mild cognitive impairment. The hypothesis is that cognitive training can improve the cognition of persons with mild cognitive impairment and that this improvement can be enduring.

NCT ID: NCT01436552 Recruiting - Clinical trials for Mild Cognitive Impairment

Psychopathological Risk Factors Associated With Conversion From Mild Cognitive Impairment to Dementia

FPRMCI
Start date: February 2010
Phase: N/A
Study type: Observational

Background: Dementias (Alzheimer's disease and related syndromes), in their sporadic form, have multifactorial origin. Several risk factors (RF) are currently recognized like the cardiovascular RF, some genes of susceptibility, but the impact [1] of traumatic life events (TLE), considered as psychosocial RF (Persson & Skoog, 1996; Charles et al, 2006), [2] of anxiety and/or depression, [3] of the premorbid personality (Clément et al, 2003) with his coping strategies, and [4] of the lifestyle (which results from the personality), for the moment are still underestimated. Dementia disease can be clinically preceded by a mild cognitive impairment (MCI) (Petersen et al, 1996) which is however potentially reversible. Purpose: Actually, there is no study concerning the rate of conversion from MCI to dementia according to the presence or not of TLE. The aim of this study is to assess association between TLE and conversion rate from MCI to dementia. Methods: Patients with MCI will be recruited in different memory clinics (Limoges and others) Primary outcome: Occurrence of dementia according to DSM-IV-TR criteria in MCI patients according to their cumulated score of TLE measured by EVVIE. Secondary outcomes: Occurrence of dementia in MCI patients according to various other psychopathological factors: anxiety, depression, apathy, personality features, alexithymia and resilience levels and life style. Study design: Epidemiologic cohort longitudinal and prospective multicenter study.